Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924136 | 0.88 | SIGMAR1 (0.67) | ACKR3SIGMAR1 | |
| SCHEMBL30924083 | 0.87 | ACKR3 (0.62) | ACKR3SIGMAR1ALDH1A1 | |
| SCHEMBL30924121 | 0.81 | ACKR3 (0.58) | ACKR3SIGMAR1ALDH1A1 | |
| SCHEMBL30924122 | 0.81 | ACKR3 (0.58) | ACKR3SIGMAR1ALDH1A1 | |
| SCHEMBL30924074 | 0.81 | ACKR3 (0.59) | ACKR3ALDH1A1 | |
| SCHEMBL30924102 | 0.81 | ACKR3 (0.58) | ACKR3SIGMAR1ALDH1A1 | |
| SCHEMBL30924045 | 0.81 | ACKR3 (0.62) | ACKR3SIGMAR1 | |
| SCHEMBL30924151 | 0.80 | SIGMAR1 (0.57) | ACKR3SIGMAR1ALDH1A1 | |
| SCHEMBL30924098 | 0.80 | KDM4E (0.61) | ACKR3SIGMAR1ALDH1A1 | |
| SCHEMBL30924073 | 0.80 | CHRM4 (0.59) | ACKR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618985-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | Universitat De Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024105234-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | disclosed |